Bethesda, Maryland 20892

  • Hematologic Neoplasm


Blood contains different kinds of cells, white blood cells, red blood cells, and platelets. In order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients. The process of removing white blood cells for the treatment of leukemia is called apheresis. This study will make available blood cell collections from volunteers genetically matched to various degrees with recipients in order to test and, if necessary, refine the process of removing white blood cell T-lymphocytes....

Study summary:

This protocol has been written to make available apheresis collections from volunteers matched to various degrees with recipients in order to test and, if necessary refine, the selective immunodepletion procedure prior to introducing it in a clinical trial.


- INCLUSION CRITERIA: Family members of patients admitted to NHLBI allogeneic BMT protocols. Ages 18 and older and less than age 65. Parent of patient (obligate haplotype match) OR HLA 3/6, 4/6, 5/6, or 6/6 match with patient. Research apheresis available from patient. EXCLUSION CRITERIA: Pregnancy or lactation. HLA type unknown. More than one haplotype mismatch with patient. History of any immunosuppressive disease. History of chronic viral antigenic stimulus. Venous access inadequate.



Primary Contact:

Principal Investigator
A. John Barrett, M.D.
National Heart, Lung, and Blood Institute (NHLBI)

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 12, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.